← Back to Search

Lumify for Glaucoma Side Effects

Phase 4
Waitlist Available
Led By Ze Zhang, MD
Research Sponsored by Tulane University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of primary open angle glaucoma
Age > 18 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 60 minutes after application of eye drop
Awards & highlights

Study Summary

This trial will test whether Lumify can help reduce side effects for people with glaucoma who are already using another medication.

Who is the study for?
This trial is for adults over 18 with primary open-angle glaucoma who've been using Brimonidine eye drops (0.1%, 0.15%, or 0.2%) for more than six weeks and can consent to participate. It's not for pregnant individuals, prisoners, those with recent surgeries, lid surgery or botox history, allergies to brimonidine, or use of certain eye medications within the last week.Check my eligibility
What is being tested?
The study tests Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) against a saline solution in glaucoma patients already on Brimonidine treatment. The focus is on its effects on ocular redness, intraocular pressure (IOP), and eyelid position.See study design
What are the potential side effects?
Lumify™ may cause minor eye irritation, dry mouth, drowsiness, or mild headaches as side effects based on previous knowledge about Brimonidine solutions used in similar concentrations.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with primary open angle glaucoma.
Select...
I am older than 18 years.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~60 minutes after application of eye drop
This trial's timeline: 3 weeks for screening, Varies for treatment, and 60 minutes after application of eye drop for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Intraocular pressure
Ocular redness
Secondary outcome measures
Eye discomfort
Palpebral fissure height

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Lumify ArmExperimental Treatment1 Intervention
In each subject, each eye will be randomized to receive a single drop of either Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) or a sterile balanced saline solution.
Group II: Control ArmPlacebo Group1 Intervention
In each subject, each eye will be randomized to receive a single drop of either Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) or a sterile balanced saline solution.

Find a Location

Who is running the clinical trial?

Tulane UniversityLead Sponsor
115 Previous Clinical Trials
226,442 Total Patients Enrolled
Ze Zhang, MDPrincipal InvestigatorTulane University

Media Library

brimonidine tartrate ophthalmic solution 0.025% Clinical Trial Eligibility Overview. Trial Name: NCT04007276 — Phase 4
Glaucoma Research Study Groups: Lumify Arm, Control Arm
Glaucoma Clinical Trial 2023: brimonidine tartrate ophthalmic solution 0.025% Highlights & Side Effects. Trial Name: NCT04007276 — Phase 4
brimonidine tartrate ophthalmic solution 0.025% 2023 Treatment Timeline for Medical Study. Trial Name: NCT04007276 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is brimonidine tartrate ophthalmic solution 0.025% typically prescribed for?

"Brimonidine tartrate ophthalmic solution 0.025% is a popular remedy for facial redness, and it can also be used to treat various medical conditions such as rosacea, glaucoma, suspect and open angle glaucoma (OAG)."

Answered by AI

Has the U.S. Food and Drug Administration given their stamp of approval to brimonidine tartrate ophthalmic solution 0.025%?

"Given its Phase 4 status, which implies that it has been approved by the relevant regulatory bodies, our team at Power assigned brimonidine tartrate ophthalmic solution 0.025% a score of 3 in regards to safety."

Answered by AI

Are there any previous records of experiments involving brimonidine tartrate ophthalmic solution 0.025%?

"Currently, there are 3 clinical trials in progress examining the effectiveness of brimonidine tartrate ophthalmic solution 0.025%. Two of these live experiments have advanced to Phase 3. The main base for this study is Henderson, Nevada; however, it has been expanded to 45 additional research sites."

Answered by AI

How many participants has this trial recruited thus far?

"Currently, this study is not in need of additional participants. It was initially posted on November 10th 2025 and last updated April 4th 2022. For those looking for similar trials, there are 217 studies recruiting patients with glaucoma open-angle and three clinical trials searching specifically for brimonidine tartrate ophthalmic solution 0.025% users."

Answered by AI

Is this particular experiment the initial exploration of its kind?

"Since 2021, research into brimonidine tartrate ophthalmic solution 0.025% has been conducted with the first trial completed by EMS in that same year. Subsequently, this drug received Phase 3 approval and is now being studied across 44 cities from 2 nations as part of three active trials."

Answered by AI

Is there an ongoing intake for participants in this research effort?

"This clinical trial is no longer accepting participants. It was initially posted on November 10th 2025, and the listing has most recently been updated April 4th 2022. For those looking for alternative studies, there are presently 217 trials enrolling individuals suffering with glaucoma open-angle and 3 separate ones focusing specifically on brimonidine tartrate ophthalmic solution 0.025%."

Answered by AI

Who else is applying?

What state do they live in?
Louisiana
Maine
District of Columbia
How old are they?
65+
18 - 65
What site did they apply to?
Tulane University Medical Center
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
Recent research and studies
clinicaltrials.govStudy
The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients
2025. "The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04007276.
All > Intraocular Lens > Glaucoma
~40 spots leftby Jun 2030
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top